Ligand id: 7437

Name: vedolizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vedolizumab

No information available.
Summary of Clinical Use
Approved to treat adult patients with moderate to severe ulcerative colitis or moderate to severe Crohn‘s disease.
Mechanism Of Action and Pharmacodynamic Effects
This antibody binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1) [2]. α4β7 integrin directs leukocytes to mucosal and inflamed tissues. This integrin is only expressed on subsets of leukocytes, and this is found to restrict α4β7-induced inflammatory modulation to the gut [2]. Specifically, vedolizumab inhibits binding of α4β7 expressing leukocytes to mucosal addressin cell adhesion molecule 1 (MADCAM1, a lymphocyte homing receptor) and fibronectin, but not to vascular cell adhesion protein 1 (VCAM1) [2]. This has the effect of reducing bowel inflammation in patients with indicated conditions.
External links